Coherus Oncology, Inc.

For the period ended Dec 31, 2025. Filed Mar 9, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 9, 2026

CHRS$0.64-21.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows

Consolidated Statements of Cash Flows

(in thousands)


· · Years Ended December 31,
· · 2025 · · 2024
Operating activities · · · · ·
Net income	$168,024	$28,507
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	3,924	5,276
Stock-based compensation expense	16,966	27,802
Write-down of intangible assets and remeasurement of contingent consideration liabilities, net	4,164	6,772
Loss on debt extinguishment	10,286	12,630
Gain on Sale Transactions, net (Note 6)	(338,315)	(176,589)
Inventory write-downs, net	—	14,143
Change in fair value of derivatives	12,608	5,043
Other non-cash adjustments, net	(10,328)	82
Changes in operating assets and liabilities:
Trade receivables, net	93,557	149,350
Inventory	(17,108)	(31,952)
Prepaid manufacturing	338	4,664
Other prepaid, current and non-current assets	4,772	(838)
Accounts payable	(19,556)	(3,938)
Accrued rebates, fees and reserves	(119,327)	(6,065)
TSA related operating assets and liabilities, net	64,446	—
Accrued compensation	(3,765)	1,549
Accrued and other current and non-current liabilities	(9,199)	(56,876)
Net cash used in operating activities	(138,513)	(20,440)

Investing activities
Purchases of investments in marketable securities	(103,838)	—
Proceeds from maturities of investments in marketable securities	21,462	6,200
Proceeds from sale of investments in marketable securities	—	8,688
Net cash received related to the Sale Transactions (Note 6)	470,305	227,823
Milestone payments to Junshi Biosciences	(12,500)	(12,500)
Other investing activities, net	(342)	110
Net cash provided by investing activities	375,087	230,321

Financing activities
Proceeds from 2029 Term Loan, net of debt discount and issuance costs	—	36,979
Proceeds from (repayment of) Revenue Purchase and Sale Agreement, net of issuance costs	(47,652)	36,486
Proceeds from issuance of common stock under Private Placement, net of issuance costs	7,894	—
Proceeds from issuance of common stock under Sales Agreement, net of issuance costs	—	1,455
Proceeds from purchase under the employee stock purchase plan	353	926
Taxes paid related to net share settlement	(283)	(2,476)
Redemption of 2026 Convertible Notes, including transaction costs	(233,185)	—
Repayment of 2027 Term Loans, premiums and make-whole	—	(260,387)
Other financing activities, net	(832)	43
Net cash used in financing activities	(273,705)	(186,974)

Net increase (decrease) in cash, cash equivalents and restricted cash	(37,131)	22,907
Cash, cash equivalents and restricted cash at beginning of period	126,250	103,343
Cash, cash equivalents and restricted cash at end of period	$89,119	$126,250

Supplemental disclosure of cash flow information
Cash paid for interest	$9,916	$25,376
Income taxes paid (refunded), net	$36	$(114)

Supplemental disclosures of non-cash activities
Non-cash employee bonuses settled in common stock	$—	$4,408

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.